Innovative Oncology Platform Invectys specializes in developing first-in-class immunotherapy products targeting universal tumor antigens, positioning it at the forefront of personalized cancer treatments and creating opportunities for collaboration on cutting-edge therapies.

Strong Clinical Focus With recent presentations at ASCO 2025 and awards for translational development, Invectys demonstrates a robust pipeline of clinical-stage therapies, indicating potential for partnerships in clinical trials and supply chain support.

Substantial Funding and Growth Having raised over $68 million in private funds, Invectys is financially positioned to expand research activities and scale manufacturing, creating opportunities for investors and vendors specializing in bioprocessing and clinical infrastructure.

Strategic Collaborations Partnerships with leading institutions like MD Anderson Cancer Center suggest openness to joint development efforts, providing avenues for sales in research services, specialized equipment, and clinical support solutions.

Geographic Presence Operating with subsidiaries in Paris and Houston, Invectys has a global footprint that can facilitate international collaborations, licensing, and distribution deals across multiple markets for advanced immunotherapy products.